SEARCH

SEARCH BY CITATION

References

  • 1
    Mann K., Batra A. The German Society for addiction research and addiction treatment. Addiction 2007; 103: 68.
  • 2
    Mann K., Kiefer F., Smolka M., Gann H., Wellek S., Heinz A. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Alcohol Clin Exp Res 2009; 33: 67483.
  • 3
    Batra A., Collins S. E., Torchalla I., Schroeter M., Buchkremer G. Multidimensional smoker profile and their prediction of smoking following a pharmacobehavioral intervention. J Subst Abuse Treat 2008; 35: 4152.
  • 4
    Treutlein J., Cichon S., Ridinger M., Wodarz N., Soyka M., Zill P. et al. Genome-wide association study of alcohol dependence. Arch Gen Psychiatry 2009; 66: 77384.
  • 5
    Vengeliene V., Kiefer F., Spanagel R. D-cycloserine facilitates extinction of conditioned alcohol-seeking behaviour in rats. Alcohol Alcohol 2008; 43: 6269.
  • 6
    Von der Goltz C., Kiefer F. Learning and memory in the etiopathogenesis of addiction: future implications for therapy? Eur Arch Psychiatry Clin Neurosci 2009; 259(suppl): S1837.
  • 7
    Kiefer F., Wiedemann K. Neuroendocrine pathways of addictive behaviour. Addict Biol 2004; 9: 20512.
  • 8
    Mann K., Ackermann K., Croissant B., Mundle G., Nakovics H., Diehl A. Neuroimaging of gender differences in alcohol dependence: are women more vulnerable? Alcohol Clin Exp Res 2005; 29: 896901.
  • 9
    Ende G., Walter S., Welzel H., Demirakca T., Wokrina T., Ruf M. et al. Alcohol consumption significantly influences the MR signal of frontal choline-containing compounds. Neuroimage 2006; 32: 7406.
  • 10
    Grüsser S. M., Wrase J., Klein S., Hermann D., Smolka M. N., Ruf M. et al. Cue-induced activation of the striatum and medial prefrontal cortex predicts relapse in abstinent alcoholics. Psychopharmacology 2004; 175: 296302.
  • 11
    Heinz A., Reimold M., Wrase J., Hermann D., Croissant B., Mundle G. et al. Correlation of stable elevations in striatal {micro}-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 2005; 62: 5764.
  • 12
    Smolka M. N., Buhler M., Klein S., Zimmermann U., Mann K., Heinz A. et al. Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology 2006; 184: 57788.
  • 13
    Hermann D., Sartorius A., Welzel H., Walter S., Skopp G., Ende G. et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry 2007; 61: 12819.
  • 14
    Kiefer F., Jahn H., Otte C., Naber D., Wiedemann K. Hypothalamic–pituitary–adrenocortical axis activity: a target of pharmacological anti-craving treatment? Biol Psychiatry 2006a; 60: 746.
  • 15
    Kiefer F., Jahn H., Otte C., Nakovics H., Wiedemann K. Effects of treatment with acamprosate on β-endorphin plasma concentration in humans with high alcohol preference. Neurosci Lett 2006b; 404: 1036.
  • 16
    Zimmermann U. S., Mick I., Laucht M., Vitvitskiy V., Plawecki M. H., Mann K. F. et al. Offspring of parents with an alcohol use disorder prefer higher levels of brain alcohol exposure in experiments involving computer-assisted self-infusion of ethanol (CASE). Psychopharmacology 2009; 202: 68997.
  • 17
    Mann K., Loeber S., Croissant B., Kiefer F. Qualified Alcohol Detoxification of Alcohol Dependent Patients—Psychotherapeutic and Pharmacological Strategies—A Manual. Köln: Deutscher Ärzteverlag; 2006.
  • 18
    Stetter F., Mann K. Zum Krankheitsverlauf Alkoholabhängiger nach einer stationären Entgiftungs- und Motivationsbehandlung [Dependency outcome of alcohol-dependent patients after inpatient detoxification and motivation treatment]. Nervenarzt 1997; 68: 57481.
  • 19
    Loeber S., Duka T. Acute alcohol impairs conditioning of a behavioural reward seeking response and inhibitory control processes—implications for addictive disorders. Addiction 2009; 104: 201322.
  • 20
    Mann K., Schafer D. R., Langle G., Ackermann K., Croissant B. The long-term course of alcoholism, 5, 10 and 16 years after treatment. Addiction 2005; 100: 797805.
  • 21
    Loeber S., Croissant B., Heinz A., Mann K., Flor H. Cue exposure in the treatment of alcohol dependence: effects on drinking outcome, craving and self-efficacy. Br J Clin Psychol 2006; 45: 51529.
  • 22
    Brueck G., Mann K. Alkoholismusspezifische Psychotherapie: Manual Mit Behandlungsmodulen. Köln: Deutscher Ärzteverlag; 2006.
  • 23
    Loeber S., Duka T. Extinction learning of stimulus reward contingencies: the acute effects of alcohol. Drug Alcohol Depend 2009; 102: 5662.
  • 24
    Sass H., Soyka M., Mann K., Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53: 67380.
  • 25
    Gastpar M., Bonnet U., Boening J., Mann K., Schmidt L. G., Soyka M. et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002; 22: 5928.
  • 26
    Bender S., Scherbaum N., Soyka M., Ruther E., Mann K., Gastpar M. The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients. Int J Neuropsychopharmacol 2006; 10: 65360.
  • 27
    Soyka M., Koller G., Schmidt P., Lesch O. M., Leweke M., Fehr C. et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 2008; 28: 31724.
  • 28
    Mann K., Ackermann K., Diehl A., Ebert D., Mundle G., Nakovics H. et al. Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology 2006; 184: 11521.
  • 29
    Diehl A., Nakovics H., Croissant B., Batra A., Smolka M., Mann K. Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. Int J Clin Pharmacol Ther 2006; 44: 61422.
  • 30
    Garbutt J. C., Kranzler H. R., O'Malley S. S., Gastfriend D. R., Pettinati H., Silverman B. L. et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 161725.
  • 31
    Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs 2004; 18: 485504.
  • 32
    Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behaviour. Physiol Rev 2009; 89: 649705.
  • 33
    Spanagel R., Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 2008; 29: 10915.
  • 34
    Mann K., Lehert P., Morgan M. Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 5163.
  • 35
    Soyka M., Gorelick D. A. Why should addiction medicine be an attractive field for young physicians? Addiction 2009; 104: 16972.